Powerock Pharma TESAMORELIN 5 mg
Powerock Pharma provides highest purity Tesamorelin, which targets visceral fat reduction by stimulating pulsatile growth hormone release to improve muscle definition while optimizing IGF-1 levels, supporting effective body recomposition under research conditions.
TESAMORELIN 5 mg
TESAMORELIN is a highly specific research peptide, acting as a stable analog of growth hormone-releasing hormone (GHRH). This compound was designed for advanced research on visceral fat reduction and metabolic optimization. Its action is based on stimulating the pituitary gland for a pulsatile release of endogenous growth hormone, allowing for precise targeting of adipocytes located within the abdominal area. This unique property makes Tesamorelin a key reagent in experiments regarding body composition recomposition, lipolysis, and GH-IGF-1 axis physiology.
Tesamorelin Powerock Pharma - Properties
Discover the potential laboratory properties of Tesamorelin that can support research on stubborn fat reduction and muscle structure definition improvement.
Visceral Fat Reduction
Demonstrates strong affinity for reducing adipose tissue in the abdominal area in research models.
GH-IGF-1 Axis Stimulation
Causes a natural, pulsatile release of growth hormone, translating into increased IGF-1 levels.
Lipid Profile Improvement
Studies observe optimization of triglyceride levels and improved glucose metabolism.
Muscle Protection
Promotes preservation and even growth of lean body mass (LBM) during reduction processes.
Physique Quality
Supports research on improving muscle density and definition through lipolytic mechanisms.
Research Safety
Mechanism of action minimizes the risk of side effects typical for synthetic HGH.
High Purity
≥98% purity confirmed by HPLC/MS methods for precise experimental results.
Pharmaceutical Standard
Manufactured according to GMP, HACCP, and ISO 13485 standards exclusively for research purposes.
How Tesamorelin Works (Chemical Mechanism)
- GHRH Analog: Selectively binds to receptors in the anterior pituitary gland, mimicking the natural secretion rhythm.
- Targeted Lipolysis: Triggers a metabolic cascade leading to fatty acid oxidation, particularly in the visceral area.
- IGF-1 Increase: Elevating Insulin-like Growth Factor-1 levels supports tissue regeneration and protein synthesis in the model organism.
- No impact on ghrelin: Unlike some GHRP peptides, it does not stimulate the hunger center, facilitating reduction studies.
- Glucose Homeostasis: Shows less impact on insulin resistance compared to direct growth hormone administration.
Why Choose Tesamorelin 5 mg from Powerock Pharma?
At Powerock Pharma, our priority is delivering only the highest quality peptide reagents. Every batch of Tesamorelin is manufactured in laboratories compliant with GMP, HACCP, and ISO 13485 standards. Our strict quality control supervision (HPLC, MS) ensures peptide stability, which is crucial for the safety and reliability of conducted experiments. Collaboration with leading research facilities guarantees purity ≥98%, allowing for durable and reproducible results, free from impurities that could disturb IGF-1 level readings. By choosing Powerock Pharma, you bet on excellence, chemical purity, and professional support for your research.
Research Protocol
Application Method:
Tesamorelin is a lyophilisate requiring reconstitution with bacteriostatic water. In laboratory conditions, the solution is administered via subcutaneous injection (s.c.) according to the established protocol.
Application Time:
To maintain metabolic data consistency, administration at a fixed time is recommended – most commonly in the morning on an empty stomach or before the subject's rest period.
Research Cycle Length:
The recommended observation period for Tesamorelin is 12–24 weeks. This time allows for a full assessment of changes in visceral fat structure and stabilization of IGF-1 levels.
Recommended Amount for Model A:
In studies on Model A (female), the suggested starting dose is 1 mg (1000 mcg) daily, with the possibility of titration based on individual response.
Recommended Amount for Model B:
For Model B (male), the standard research dose, based on clinical literature, is 2 mg (2000 mcg) daily. This dose shows the highest efficacy in reducing lipodystrophy.
Parameter Monitoring:
Regular determination of IGF-1 and blood glucose levels in test subjects is crucial. All changes in body measurements and reactions at the injection site should be documented.
Frequently Asked Questions
- Clinical standards suggest using 2 mg daily for Model B and 1 mg for Model A. These values can be adjusted depending on the experiment's goal (e.g., anti-aging vs. tissue reduction).
- For synergistic fat-burning effects, Tesamorelin is often combined in studies with Ipamorelin or Fragment 176-191. For regenerative (systemic) purposes, a combination with BPC-157 is used.
- Redness or itching at the injection site, mild joint pain, or transient water retention may occur. These symptoms usually subside during the research cycle.
- Studies indicate a high safety profile when used for 6-12 months. However, continuous monitoring of glycemia and IGF-1 levels is important to keep parameters within physiological norms.
- Store unconstituted powder in the refrigerator (2–8°C). After reconstitution, the solution is unstable – it must remain refrigerated and be used within 14-30 days (depending on the solvent used). Protect from light.
- No. The product is a chemical reagent intended exclusively for laboratory research and in vitro or animal experiments. It is not a drug or a dietary supplement.
Calculator for measuring research doses
Tip: 1 MG = 1000 MCG
